Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $152.15 | Total: $760.75 |
| 1 | 10 | $128.88 | Total: $1,288.80 |
| 1 | 25 | $109.19 | Total: $2,729.75 |
| 1 | 50 | $93.08 | Total: $4,654.00 |
| 1 | 100 | $80.55 | Total: $8,055.00 |
Overview
AZD-1305 is a novel anti-arrhythmic compound that primarily blocks the fast component of IKr, l-type calcium currents and intra-ward sodium currents in mammalian cells and ventricular cardiomyocytes and can be used in studies to reverse arrhythmias.
Chemical Properties
| Molecular Formula | C22H31FN4O4 |
| Molecular Weight | 434.5 |
| CAS Numbers | 872045-91-5 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | C(COC1=C(F)C=C(C#N)C=C1)N2CC3OC(CN(CCNC(OC(C)(C)C)=O)C3)C2 |
Storage and Handling
0C Short Term, -20C Long Term
References
Sigfridsson K, et al. Preformulation evaluation of AZD1305, an oxabispidine intended for oral and intravenous treatment. Drug Dev Ind Pharm. 2012 ; 38[1] 19-31.